Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors

Bibliography

• FISHER RA, BERTONIS JM, MEIER W et al.: HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 331:76–78.
   PubMed Web of Science ®Google Scholar
• HUSSEY RE, RICHARDSON NE, KOWALSKI M et al: A soluble CD4 protein selectively inhibits HIV replica-tion and syncytium formation. Nature (1988) 331:78–81.
   PubMed Web of Science ®Google Scholar
• DEEN KC, MCDOUGAL JS, INACKER R et al: A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 331:82–84.
   PubMed Web of Science ®Google Scholar
• TRAUNECKER A, LUKE W, K KARJALAINEN: Soluble CD4 molecules neutralize 11IV-1. Nature (1988) 331:84–86.
   PubMed Web of Science ®Google Scholar
• JOHNSON VA, BARLOW MA, CHOU TC et al: Synergistic inhibition of 11IV-1 replication in vitro by recombi-nant soluble CD4 and 30-azido-30-deoythymidine. J. Infect. Dis. (1989) 159:837–44.
   PubMed Web of Science ®Google Scholar
• KAHN JO, ALLAN JD, HODGES TL et al.: The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with AIDS and AIDS-related complex. Ann. Intern. Med. (1990)112:254–61.
   PubMed Web of Science ®Google Scholar
• SCHOOLEY RT, MERIGAN TC, GAUT P et al.: Recombi-nant soluble CD4 therapy in patients with AIDS and AIDS-related complex. Ann. Intern. Med. (1990) 112:247–253.
   PubMed Web of Science ®Google Scholar
• KWONG PD, WYATT R, ROBINSON J, SWEET RW, SODROSKI J, WA HENDRICKSON: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 393:648–659.
   PubMed Web of Science ®Google Scholar
• ••These important papers provide new detailed descriptionsof the glycprotein structures of HIV-1 using novel analytical strategies, opening the door for future therapeutic strategies aimed at blocking viral entry.
   Google Scholar
• WYATT R, J SODROSKI: The 11IV-1 envelope glycopro- teins: fusogens, antigens, and immunogens. Science (1998) 280: 1884-1888.
   Google Scholar
• ••See reference [8] for annotation.
   Google Scholar
• MENG T-C, FISCHL MA, CHEESEMAN SH et al.: Combina-tion therapy with recombinant human soluble CD4-Immunoglobulin g and zidovudine in patients with HIV infection: a Phase I study. J. Acquit-. Imm. Deficien. Syndr. (1995) 8:1520160.
   Google Scholar
• SHEARER MH, TIMANUS DK, BENTON PA, LEE DR, RC KENNEDY: Cross-clade inhibition of 11IV-1 primary isolates by monoclonal anti-CD4. J. Infect. Dis. (1998) 177:1727–1729.
   PubMed Web of Science ®Google Scholar
• BABA M, PAUWELS R, BALZARINI J et al.: Mechanisms of inhibitory effect of dextran sulfate and heparin on replication of HIV in vitro. Proc. Natl. Acad. Sci. USA (1988) 85:6132–6136.
   PubMed Web of Science ®Google Scholar
• MITSUYA H, LOONEY DJ, KUNO S et al.: Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science (1988) 240:646–9.
   PubMed Web of Science ®Google Scholar
• BABA M, SNOECK R, PAUWELS R et al.: Sulfated polysac-charides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob. Agents Chemother. (1988) 32:1742–1745.
   PubMed Web of Science ®Google Scholar
• ABRAMS DI, KUNO S, WONG R et al.: Oral dextran sulfate (UA001) in the treatment of the acquired immunodefi-ciency syndrome (AIDS) and AIDS-related complex. Ann. Intern. Med. (1989) 110:183–188.
   PubMed Web of Science ®Google Scholar
• LORENTSEN KJ, HENDRIX CW, COLLINS JM et al.: Dextran sulfate is poorly absorbed after oral administration. Ann. Int. Med. (1989) 111:561–566.
   PubMed Web of Science ®Google Scholar
• FLEXNOR C, BARDITCH-CROVO PA, KORNHAUSER DM etPharmacokinetics, toxicity, and activity of intrave-nous dextran sulfate in human immunodeficiency virus infection. Antimicrob. Agents Chemother. (1991) 35:2544–1550.
   PubMedGoogle Scholar
• MEYLAN PRA, KORNBLUTH RS, ZBINDEN I, DD RICHMAN: Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of 11IV-1 to polyanion compounds. Anticrob. Agents Chemother. (1994) 38:2910–2916.
   PubMed Web of Science ®Google Scholar
• RUSCONI S, MOONIS M, MERRILL DP et al.: Naphthalene sulfonate polymers with CD4 -blocking and anti-human immunodeficiency virus Type 1 activities. Antimicrob. Agents Chemother. (1996) 40:234–236.
   PubMed Web of Science ®Google Scholar
• ONO M, WADA Y, WU Y et al: FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes. Nature Biotechnol. (1997) 15:343–348.
   PubMed Web of Science ®Google Scholar
• COCCHI F, DEVICO AL, GARZINO-DEMO A, ARYA SK, GALLO RC, P LUSSO: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ cells. Science (1995) 270: 1811-1815.
   Google Scholar
• ••One of the first papers to demonstrate the HIV inhibitoryeffects of the I3-chemokines, prior to the discovery of the HIV chemokine co-receptor
   Google Scholar
• PAL R, GARZINO-DEMO A, MARKHAM PD, BURNS J, BROWN M, GALLO RC, AL DEVICO: Inhibition of 11IV-1 infection by the Beta chemokine MDC. Science (1997) 278:695–98.
   PubMed Web of Science ®Google Scholar
• ARENZANA-SEISEDOS F, VIRELIZIER JL, ROUSSET D et al.:HIV blocked by chemokine antagonist. Nature (1996) 383:400.
   PubMed Web of Science ®Google Scholar
• SIMMONS G, CLAPHAM PR, PICARD L etal. Potent inhibi- tion of 11IV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276:276–279.
   Google Scholar
• DRAGIC T, LITWIN V, ALLAWAY GP et al.: 11IV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667–673.
   PubMed Web of Science ®Google Scholar
• •Independent groups of investigators discover the importance of the chemokine nexus in HIV pathogenesis, revealing that CCR5 and CXCR4 are key receptors for HIV isolates that are "M-tropic" or "T-tropic", respectively.
   Google Scholar
• DENG HK, LIU R, ELLMEIER W et al: Identification of a major co-receptor for primary isolates of 11IV-1. Nature (1996) 381:661–666.
   PubMed Web of Science ®Google Scholar
• •See reference [25] for annotation.
   Google Scholar
• FENG Y, BRODER CC, KENNEDY PE, EA BERGER: 11IV-1 entry cofactor: functional cDNA cloning of a sever-transmembrane G protein-coupled receptor. Science (1996) 272:872–877.
   PubMed Web of Science ®Google Scholar
• •See reference [25] for annotation.
   Google Scholar
• BLEUL CC, FARZAN M, CHOE H et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks 11IV-1 entry. Nature (1996) 382:829–833.
   PubMed Web of Science ®Google Scholar
• •See reference [25] for annotation.
   Google Scholar
• OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted 11IV-1. Nature (1996) 382:833–835.
   PubMed Web of Science ®Google Scholar
• •See reference [25] for annotation.
   Google Scholar
• DERDEYN CA, COSTELLO C, SFAKIANOS G et al.: Correla- tion between circulating SDF-1 levels and CD4 count in 11IV-1-infected individuals. AIDS Res. Human Retrov. In press.
   Google Scholar
• AMARA A, GALL SL, SCHWARTZ O et al.: HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. (1997) 186(1):139–146.
   PubMed Web of Science ®Google Scholar
• TRKOLA A, PAXTON WA, MONARD SP et al.: Genetic subtype-independent inhibition of human immuno-deficiency virus Type 1 replication by CC and CXC chemokines. j Vim]. (1998) 72(0:396–404.
   Google Scholar
• CHEN JD, BAI X, YANG AG et al: Inactivation of 11IV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nature Med. (1997) 3 (10) :1110–1116.
   PubMed Web of Science ®Google Scholar
• CARROLL R, RILEY J, LEVINE B et al: Differential regula-tion of 11IV-1 fusion cofactor expression by CD28 costimulation of CD4 + T cells. Science (1997) 276:273–279.
   PubMed Web of Science ®Google Scholar
• WU L, LAROSA G, KASSAM N et al.: Interaction of chemokine receptor CCR5 with its ligands: multiple domains for 11IV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. (1 9 9 7) 186(8):1373–1381.
   Google Scholar
• MARGOLIS L, GLUSHAKOVA S, GRIVEL JC et al: Blockade of CC chemokine receptor 5 (CCR5) - tropic human immunodeficiency virus - 1 replication in human lymphoid tissue by CC chemokines. J. Clin. Inv. (1998) 101:1876–1880.
   PubMed Web of Science ®Google Scholar
• MURAKAMI T, NAKAJIMA T, KOYANAGI Y et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic 11IV-1 infection. J. Exp. Med. (1997) 186:1389–1393.
   PubMed Web of Science ®Google Scholar
• ARAKAKI R, TAMAMAURA H, PREMANATHAN M et al.: T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Vim]. (1999) 73:1719–1723.
   Web of Science ®Google Scholar
• DORANZ BJ, GROVIT-FERBAS K, SHARRON MP et al.: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an 11IV-1 coreceptor. J. Exp. Med. (1997) 186(8):1395–1400.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E, YAMAMOTO N, PAUWELS R et al.: Potent and selective inhibition of human immunodeficiency virus (11IV)-1 and 11IV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. USA (1992) 89:5286–5290.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E, YAMAMOTO N, PAUWELS R et al.: Highly potent and selective inhibition of human immunodefi-ciency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. (1994) 38:668–674.
   PubMed Web of Science ®Google Scholar
• DE VREESE K, VAN NERUM I, VERMEIRE K et al.: Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120. Antimicrob. Agents Chemother. (1997) 41:2616–2620.
   PubMed Web of Science ®Google Scholar
• DONZELLA G, SCHOLS D, LIN S et al.: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. (1998) 4:72–77.
   PubMed Web of Science ®Google Scholar
• ••The first in vitro evidence that a small molecule couldeffectively target the binding of T-tropic strains of HIV to the CXCR4 receptor.
   Google Scholar
• ESTE J, CARERA C, HENSON G et al: Anti-HIV activity of AMD3465, a novel antagonist of the CXCR4 receptor. Int. Conf. AIDS (1998) 12578–779. Abstract 41183.
   Google Scholar
• LABROSSE B, BRELOT A, HEVEKER N et al.:Determinants for sensitivity of HIV coreceptor CXCR4 to the bicyclam AMD3100. j Vim]. (1998) 72:6381–6388.
   Web of Science ®Google Scholar
• MACKEWICZ CE, BARKER E LEVY JA: Role of beta-chemokines in suppressing HIV replication. Science (1996) 174:1393–1395.
   Web of Science ®Google Scholar
• PAXTON WA, MARTIN SR, TSE D et al: Relative resistance to 11IV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nature Med. (1996) 2:412–417.
   PubMed Web of Science ®Google Scholar
• •Significant insights regarding the mechanisms of HIV entry into cells were based on analyses of the exceptional cases of human subjects who were frequently exposed to HIV and yet seemed to have at least partial "immunity" to infection. Some of these subjects have a phenotype resulting in altered expression of the chemokine receptors that are critical for HIV entry into cells.
   Google Scholar
• DEAN M, CARRINGTON M, WINKLER C et al.: Genetic restriction of 11IV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science (1996) 273: 1856-1862.
   Google Scholar
• •See reference [47] for annotation.
   Google Scholar
• LIU R, PAXTON A, CHOE S et al.: Homozygous defect in 11IV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 86:367–378.
   PubMed Web of Science ®Google Scholar
• •See reference [47] for annotation.
   Google Scholar
• NAGASAWA T, HIROTA S, TACHIBANA K et al.: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-2. Nature (1996) 382(6592):635–638.
   PubMed Web of Science ®Google Scholar
• SCARLATTI G, TRESOLDI E, BJORNDAL A et al.: In vivo evolution of 11IV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Med. (1997) 3:1259–1265.
   PubMed Web of Science ®Google Scholar
• GALLAHER W, BALL J, GARRY R, GRIFFIN M, R MONTER-LARO: A general model of the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retrovir. (1989) 5:431–440.
   PubMed Web of Science ®Google Scholar
• DELWART E, MOSIALOS G, T GILMORE: Retroviral envelope glycoproteins contain a leucine zipper'-like repeat. AIDS Res. Hum. Retroviruses (1989) 6:703–706.
   Web of Science ®Google Scholar
• •Examples of the critical, early in vitro investigations of gp41-mediated fusion that led to the development of membrane fusion inhibitors, like T-20 and T-1249, now in clinical trials.
   Google Scholar
• WILD C, GREENWELL T, SHUGARS D, RIMSKY-CLARKE T MATTHEWS: A synthetic peptide inhibitor of HIV replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA (1992) 89:10537–10541.
   PubMed Web of Science ®Google Scholar
• •See reference [53] for annotation.
   Google Scholar
• WILD C, GREENWELL T, MATTHEWS T: A synthetic peptide from 11IV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses (1993) 9:1051–1053.
   PubMed Web of Science ®Google Scholar
• •See reference [53] for annotation.
   Google Scholar
• WILD CT, SHUGARS DC, GREENWELL TK et al.: Peptides corresponding to a predictive alpha-helical domain of 11IV-1 gp41 are potent inhibitors of virus infection. Proc. Nati Acad. Sci. USA (1994) 91:9770–9774.
   PubMed Web of Science ®Google Scholar
• •See reference [53] for annotation.
   Google Scholar
• CHEN CH, MATTHEWS T, MCDANAL C et al.: A molecular clasp in 11IV-1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J. Vim]. (1995) 69:3771–3777.
   Web of Science ®Google Scholar
• LAWLESS MK et al.: 11IV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry (1995) 35:13697–13708.
   Web of Science ®Google Scholar
• MATTHEWS T et al.: Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol. Rev. (1994) 140:93–104.
   PubMed Web of Science ®Google Scholar
• WILD C, GREENWELL T, SHUGARS D etal.: The inhibitory activity of an 11IV-1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses (1995) 11:323–325.
   Google Scholar
• WILD C, OAS T, MCDANAL C et al: A synthetic peptide inhibitor of HIV replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA (1992) 89:10537–10541.
   PubMed Web of Science ®Google Scholar
• DUBAY J, ROBERTS S, BRODY B et al.: Mutations in the leucine zipper of 11IV-1 transmembrane glycoprotein affect fusion and infectivity. J. Virol. (1992) 65:4748–4756.
   Google Scholar
• WILD C et al: Propensity for a leucine zipper-like domain of 11IV-1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA (1994) 91:12676–12680.
   PubMed Web of Science ®Google Scholar
• BULLOUGH PA, HUGHSON M, SKEHEL JJ et al.: Structure of influenza haemagglutinin at the pH of membrane fusion. J. Virol. (1994) 371:37–43.
   Google Scholar
• CARR C, KIM PS: A spring-loaded mechanism for the conformational change of influenza hemaglutinin. Cell (1993) 73:823–832.
   PubMed Web of Science ®Google Scholar
• KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of 11IV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. (1998) 4:1302–1307.
   PubMed Web of Science ®Google Scholar
• ••This small clinical trial was the first demonstration thattherapies can successfully target the viral entry/membrane fusion step of HIV-1.
   Google Scholar
• LALEZARI J, ERON J, CARLSON M et al.: Safety, pharma-cokinetics, and antiviral activity of T-20 as a single agent in heavily pre-treated patients. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, USA (1999). Abstract LB13.
   Google Scholar
• RIMSKY LT, SHUGAR DC MATTHEWS T: Determinants of11IV-1 resistance to gp41-derived inhibitory peptides. Virol. (1998) 72:986–992.
   Web of Science ®Google Scholar
• WEI X, KILBY M, HOPKINS S, SAAG M, G SHAW: 11IV-1selection in response to inhibition of virus fusion and entry. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, USA (1999). Abstract 611.
   Google Scholar